Zhifei Biological Reports Strong Growth in Merck-Partnered Vaccine Batch Releases and Ongoing Collaboration

Chongqing Zhifei Biological Products Co., Ltd. recently stated in an investor research meeting that,Currently, the company's cooperation with MSD is proceeding normally. According to the batch release data for the first three quarters of 2022, the batch release volume of all agency products has achieved good growth compared to the same period last year, with significant increases in major products. For details on the renewal of agreements, please refer to the company’s announcements. The elimination of cervical cancer is a shared vision for all humanity and has been a goal that vaccine enterprises both internationally and in China have been committed to achieving. In 2020, the WHO released the "Global Strategy to Accelerate the Elimination of Cervical Cancer." In China, screening for cervical and breast cancer has been included as part of the basic public health service programs. With advancements in biomedicine testing and artificial intelligence technologies, regions across China are continuously optimizing their screening models for these two cancers. In recent years, China has been actively strengthening the scientific promotion of HPV vaccination. As awareness about cervical cancer prevention continues to grow, the research, development, supply, accessibility, and affordability of HPV vaccines have gained widespread attention and have been actively promoted.